Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Cancer Res. 2013 May 30;73(14):4439–4450. doi: 10.1158/0008-5472.CAN-13-0187

Figure 5.

Figure 5

Both ITEM4-rGel and hSGZ inhibit tumor growth and prolong survival in a MDA-MB-231/Luc breast tumor xenograft model. MDA-MB-231/luc cells were implanted subcutaneously and groups of mice (n = 5) were treated (i.v. via tail vein) with saline, ITEM-4 plus rGel, ITEM4-rGel (36 mg/kg), and hSGZ (36 mg/kg and 25 mg/kg) every 6 days starting when the tumors were approximately 100 mm3. Arrow indicates dosing days. A, efficacy data are plotted as mean tumor volume (in mm3) ± SEM. Tumor size assessed by direct caliper measurement. B, survival data are plotted as percent of animals surviving in each group using a predefined cutoff volume of 1,200 mm3 as a surrogate for survival. C, the BLI images of mice on selected days were shown. D, percent change in body weight of each group of mice is plotted as a function of time. E, Tumor tissues from the xenograft experiment in (A) were analyzed for Fn14 and GAPDH expression by Western blot.